Log In
Print this Print this

Arcalyst, Rilonacept Regeneron, rilonacept (formerly IL-1 Trap)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionRecombinant protein with the heterodimeric IL-1 receptor linked to the Fc portion of human IgG
Molecular Target Interleukin-1 (IL-1)
Mechanism of ActionInterleukin-1 (IL-1) inhibitor
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationCIAS1-associated periodic syndrome (CAPS)
Indication DetailsTreat cryopyrin-associated periodic syndrome (CAPS); Treat familial cold auto-inflammatory syndrome (FCAS); Treat Muckle-Wells syndrome (MWS)
Regulatory Designation U.S. - Orphan Drug (Treat cryopyrin-associated periodic syndrome (CAPS))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today